Trial · NCT04959799
Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)
NCT04959799, Completed, Aziende Chimiche Riunite Angelini Francesco S.p.A
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA). Trials, record NCT04959799. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04959799
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)
- NCT number
- NCT04959799
- Status
- Completed
- Enrollment
- 98 participants, actual
- Lead sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- Conditions
- Diabetes, Infection
- Interventions
- Dalbavancin
- First posted
- 2021-07-13
- Last updated
- 2022-09-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Retrospective description of the dalbavancin treatment in diabetic patients. | 4 weeks | Evidence of dalbavancin treatment choice (number and dates of infusions) |
| Primary | Retrospective description of the utilization of dalbavancin treatment in diabetic patients. | 4 weeks | Evidence of dalbavancin treatment choice (starting and subsequent dosage) |
| Primary | Retrospective description of the setting of dalbavancin treatment in diabetic patients. | 4 weeks | Evidence of dalbavancin treatment choice (setting of infusion) |
| Secondary | Demographic data | 4 weeks | Demographic data description (Age and Gender) |
| Secondary | Clinical cure of dalbavancin | Up to 8 weeks | Number of patients with clinical cure evaluated by physicians at end of dalbavancin treatment (i.e., date of last dalbavancin dose administration). Clinical cure is defined as clinical signs and symptoms resolved. |
| Secondary | Microbiological success of dalbavancin | Up to 8 weeks | Number of patients with microbiological success at end of dalbavancin treatment (i.e., date of last dalbavancin dose administration). Microbioligical success is defined as culture-confirmed eradication of the Gram-positive pathogens identified at baseline, documented as a negative bacterial culture from the same site as the initial positive baseline culture |
| Secondary | Incidence of Adverse Events | Up to 8 weeks | Safety profile was assessed through the incidence of Adverse Events occurred in patients treated with dalbavancin. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38211660 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04959799
GET https://conductscience.org/api/trials/v1/NCT04959799/registered